Evaluation of DNA Methylation as a Target for Intraductal Therapy for Ductal Carcinoma in Situ of the Breast
Final rept. 15 Jul 2002-15 Jul 2006
NEW YORK UNIV NY SCHOOL OF MEDICINE
Pagination or Media Count:
In ductal carcinoma in situDCIS, the malignant cells are confined within the basement membrane, and so an ideal candidate for local therapies. Because DNA methylation is a potentially reversible mechanism for tumor suppressor gene inactivation, it is an intriguing target for molecular therapeutics. In this study we have documented significant methylation in eight tumor suppressor genes in DCIS. We have successfully performed ductal lavage in 2427 patients undergoing surgery for DCIS without any complications. Unfortunately, we were able to successfully identify and lavage the malignant duct in only 25 of cases, half of which were identified because the patient presented with discharge. In the absence of nipple discharge, only 14 of the lavaged ducts were the malignant duct. While these data do not rule out the potential of targeting DNA methylation for intraductal therapy for DCIS, we need better methods for identifying the malignant ductal orifices before proceeding to clinical trials of intraductal therapy.
- Medicine and Medical Research